{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:48:45Z","timestamp":1759333725627,"version":"build-2065373602"},"reference-count":5,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jaad.2022.05.005","type":"journal-article","created":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T23:20:10Z","timestamp":1652138410000},"page":"1125-1127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tofacitinib therapy for alopecia areata is not associated with adverse events during COVID-19 infection"],"prefix":"10.1016","volume":"88","author":[{"given":"Soundos","family":"Youssef","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Lavian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunice Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijia","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey A.","family":"Bordone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2022.05.005_bib1","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2147\/CCID.S309215","article-title":"A comprehensive literature review of JAK inhibitors in treatment of alopecia areata","volume":"14","author":"Dillon","year":"2021","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2022.05.005_bib2","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2022.05.005_bib3","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14746","article-title":"Evaluation of the alopecia areata patients on tofacitinib treatment during the COVID-19 pandemic","volume":"34","author":"A\u015fk\u0131n","year":"2021","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1016\/j.jaad.2022.05.005_bib4","doi-asserted-by":"crossref","first-page":"234","DOI":"10.4103\/ijt.ijt_67_20","article-title":"Validation of case identification for alopecia areata using international classification of diseases coding","volume":"12","author":"Lavian","year":"2020","journal-title":"Int J Trichology"},{"issue":"3","key":"10.1016\/j.jaad.2022.05.005_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247461","article-title":"Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis","volume":"16","author":"Booth","year":"2021","journal-title":"PLoS One"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222007952?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222007952?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:25:09Z","timestamp":1759274709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962222007952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":5,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0190962222007952"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2022.05.005","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tofacitinib therapy for alopecia areata is not associated with adverse events during COVID-19 infection","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2022.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}